- The epigenetic market had approximately USD 4 billion value by size in 2014 and is estimated to rise at 19% CAGR in the future. The major drive to the epigenetics market is the rising occurrence of cancer. Epigenetics has initiated R&D for various therapeutic drugs for autoimmune & chronic disorder and cancer. Diagnostic companies are being collaborated with biopharmaceutical companies to develop therapeutics on the basis of epigenetic biomarkers.
For Market Research Report on “Epigenetics Market” Visit -http://www.grandviewresearch.com/industry-analysis/epigenetics-market
This type of initiative is expected to extensively improvise the penetration rates in the future. The other areas of market growth are investments and technological advancement of R&D and development of drugs. At present, histone modification and discovery of DNA methylation patterns are the vital focal points.
Some benefits are there in these techniques. They are same gene quantification of un-methylated DNA; blood fluids DNA; and tumor detection which works as reference of epigenetic change detection. Usage rates are also estimated to be improved by specific antibodies development for precise and quick detection of histone core proteins modification.
The market is divided into products, technologies, applications, and regions. The key product sectors of this technology include reagents, kits, enzymes, instruments, and services. The most profitable sector was reagents in 2014 with more than 30% of total market owing to usages of different reagents like acetylation, DNA methylation, and histone methylation in reaction techniques.
The fastest growth is estimated from kits sector with more than 19% over the forecast period. Kit production is done with the use of advanced technology by the companies for fast and accurate detection with the help of small samples.
The technology sector includes Chromatin structures, DNA Methylation, MicroRNA modification, Histone Methylation, Large noncoding RNA, and Histone Acetylation. The major technology used was DNA Methylation in 2014 with over USD 1850.0 million.
Application wise the solid tumors had the major share in 2014. Liquid tumor treatment is presenting an opportunity as well with more than 20% CAGR over the forecast period. Metabolic diseases, cardiovascular diseases, inflammatory diseases, infectious diseases, etc are the sub-sectors of Non-oncology sector. With more than 32% share metabolic diseases was the biggest in 2014.
North America had the biggest regional market with more than 38% in 2014. Europe followed North America. Asia Pacific has the most profitable market due to high population along with cancer, cardiovascular disease, diabetes, etc. The major players are Sigma-Aldrich Corporation, Illumina, Abcam, Valirx Plc, Qiagen, Syndax Pharmaceuticals, and others.
Information Source: Grand View Research
To request a sample copy of this report, please complete the form below.
To purchase a copy of this report, please contact at
28 2nd Street, Suite 3036
San Francisco, CA 94105
Toll Free: 1-888-202-9519